The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Nurtdinova G.M.

Bashkir State Medical University

Galimova E.S.

Bashkir State Medical University

Kucher O.I.

City Clinical Hospital No. 21

Nugumanova Z.R.

City Clinical Hospital No. 21

Valeeva R.I.

City Clinical Hospital No. 21

Gazizova D.D.

Bashkir State Medical University

Galyautdinov A.F.

Bashkir State Medical University

Sadykova K.F.

Bashkir State Medical University

Khismatullina Z.R.

Bashkir State Medical University of the Ministry of Healthcare of the Russian Federation

Zagidullin N.S.

Bashkir State Medical University

Risk factors for Stevens — Johnson syndrome and toxic epidermal necrolysis

Authors:

Nurtdinova G.M., Galimova E.S., Kucher O.I., Nugumanova Z.R., Valeeva R.I., Gazizova D.D., Galyautdinov A.F., Sadykova K.F., Khismatullina Z.R., Zagidullin N.S.

More about the authors

Read: 699 times


To cite this article:

Nurtdinova GM, Galimova ES, Kucher OI, et al. Risk factors for Stevens — Johnson syndrome and toxic epidermal necrolysis. Russian Journal of Clinical Dermatology and Venereology. 2025;24(5):608‑614. (In Russ.)
https://doi.org/10.17116/klinderma202524051608

Recommended articles:
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Cere­bral venous thro­mbosis in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):11-19
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Features of professional adaptation of doctors begi­nning their work acti­vities. Russian Journal of Preventive Medi­cine. 2025;(9):112-118
Predictors of adve­rse outcomes after severe traumatic brain injury. Burdenko's Journal of Neurosurgery. 2025;(5):71-78
Redo asce­nding aortic surgery: outcomes and risk factors of complications. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):511-519

References:

  1. Harr T, French LE. Stevens-Johnson Syndrome and toxic epidermal necrolysis. Chemical Immunology and Allergy. Published online. 2012:149-166.  https://doi.org/10.1159/000335627
  2. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Journal of the American Academy of Dermatology. 2013;69(2):173.e1-173.e13.  https://doi.org/10.1016/j.jaad.2013.05.003
  3. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens–Johnson Syndrome and toxic Epidermal necrolysis: an update. American Journal of Clinical Dermatology. 2015;16(6):475-493.  https://doi.org/10.1007/s40257-015-0158-0
  4. Sunaga Y, Kurosawa M, Ochiai H, et al. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. Journal of Dermatological Science. 2020;100(3):175-182.  https://doi.org/10.1016/j.jdermsci.2020.09.009
  5. Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson Syndrome and toxic epidermal necrolysis: A Nationwide Population-Based Study using National Health Insurance Database in Korea. PLoS ONE. 2016;11(11): e0165933. https://doi.org/10.1371/journal.pone.0165933
  6. Cabañas Weisz LM, Miguel Escuredo I, Ayestarán Soto JB, García Gutiérrez JJ. Toxic epidermal necrolysis (TEN): Acute complications and long-term sequelae management in a multidisciplinary follow-up. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2020;73(2):319-327.  https://doi.org/10.1016/j.bjps.2019.07.015
  7. De Jesus LE, Dekermacher S, Manhães CR, Faria LM, Barros ML. Acquired labial sinechiae and hydrocolpos secondary to Stevens-Johnson syndrome. Urology. 2012;80(4):919-921.  https://doi.org/10.1016/j.urology.2012.06.051
  8. Zimmermann S, Sekula P, Venhoff M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology. 2017;153(6):514.  https://doi.org/10.1001/jamadermatol.2016.5668
  9. Soo Jie Chung, Ahn K, Ji Hyun Oh, Shim J, Park H. Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: A nationwide study using health claims data in Korea. Epilepsia. 2020;62(1):250-257.  https://doi.org/10.1111/epi.16751
  10. Gronich N, Maman D, Stein N, Saliba W. Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study. American Journal of Clinical Dermatology. 2022;23(2):257-266.  https://doi.org/10.1007/s40257-021-00661-0
  11. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens–Johnson Syndrome and HIV in Children in Swaziland. Pediatric Infectious Disease Journal. 2013;32(12):1354-1358. https://doi.org/10.1097/inf.0b013e31829ec8e5
  12. Carrasquillo OY, Santiago‐Vazquez M, Cardona R, Cruz‐Manzano M, Figueroa LD. Stevens‐Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. International Journal of Dermatology. 2019; 58(11):1293-1299. https://doi.org/10.1111/ijd.14493
  13. Chan L, Cook DK. A 10‐year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens‐Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. International Journal of Dermatology. 2019;58(10):1141-1147. https://doi.org/10.1111/ijd.14426
  14. Lim VM, Do A, Berger TG, et al. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. Burns. 2016;42(4):836-843.  https://doi.org/10.1016/j.burns.2016.01.014
  15. Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis—ABCD-10. JAMA Dermatology. 2019;155(4):448.  https://doi.org/10.1001/jamadermatol.2018.5605
  16. Lalosevic J, Nikolic M, Gajic‐Veljic M, Skiljevic D, Medenica L. Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience. International Journal of Dermatology. 2014;54(8):978-984.  https://doi.org/10.1111/ijd.12702
  17. Nizamoglu M, Ward JA, Frew Q, et al. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. Burns. 2018;44(3):603-611.  https://doi.org/10.1016/j.burns.2017.09.015
  18. Rausch J, Lopez PA, Bialojan A, et al. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization. Journal of Dermatological Science. 2017;87(3):300-306.  https://doi.org/10.1016/j.jdermsci.2017.06.013
  19. Gan X, Shan Q, Li H, et al. An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(32). https://doi.org/10.1073/pnas.2200879119
  20. Kumar P, Saini S, Prabhakar BS. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Seminars in Cancer Biology. 2020;64:29-35.  https://doi.org/10.1016/j.semcancer.2019.01.006
  21. He C, Si X, Zhang L, Xu Y, Qu T. Immune checkpoint inhibitor–related epidermal necrolysis: A rare condition with poor prognosis. European Journal of Cancer. 2021;145:194-196.  https://doi.org/10.1016/j.ejca.2020.12.018
  22. Logan IT, Zaman S, Hussein L, Perrett CM. Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: a case report and literature review. Journal of Immunotherapy. 2019;43(3):89-92.  https://doi.org/10.1097/cji.0000000000000302
  23. Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics in Dermatology. 2020;38(1):94-104.  https://doi.org/10.1016/j.clindermatol.2019.10.015
  24. HIV 2014/2015. Eds. K Hoffmann, JK Rockstroh. Hamburg, Bonn: Medizin Fokus; 2014. (In Russ.).
  25. Guo Z, Wang G, Wu B, et al. DCAF1 regulates Treg senescence via the ROS axis during immunological ageing. Journal of Clinical Investigation. 2020; 130(11):5893-5908. https://doi.org/10.1172/jci136466

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.